Table 4. Multivariable logistic regression for the initiation of adjuvant endocrine therapy among women diagnosed with stages I–III hormone receptor-positive breast cancer.
| Initiate any AET | Initiate tamoxifen | Initiate AI | ||||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| AOR | 95 % CIa | AOR | 95 % CIa | AOR | 95 % CIa | |
| Race/ethnicity | ||||||
| Non-Hispanic white | 1 | 1 | 1 | |||
| Non-Hispanic black | 0.87 | (0.72–1.04) | 0.70 | (0.54–0.91) | 1.05 | (0.89–1.23) |
| Hispanic (Mexican) | 1.38 | (0.90–2.13) | 0.25 | (0.10–0.62) | 2.06 | (1.34–3.10) |
| Hispanic (South/Central) | 0.91 | (0.55–1.50) | 0.71 | (0.34–1.49) | 1.07 | (0.68–1.70) |
| Hispanic (other/unknown) | 1.23 | (0.97–1.57) | 0.97 | (0.72–1.29) | 1.20 | (0.98–1.48) |
| Asian | 1.28 | (1.03–1.58) | 0.83 | (0.63–1.09) | 1.33 | (1.11–1.61) |
| Age (years) | ||||||
| 65–69 | 1 | 1 | 1 | |||
| 70–74 | 0.93 | (0.81–1.06) | 1.06 | (0.91–1.25) | 0.92 | (0.82–1.03) |
| 75–79 | 0.69 | (0.60–0.79) | 1.10 | (0.93–1.30) | 0.71 | (0.63–0.80) |
| 80+ | 0.47 | (0.41–0.53) | 1.13 | (0.96–1.33) | 0.50 | (0.45–0.57) |
| Marital status | ||||||
| Married | 1 | 1 | 1 | |||
| Unmarried | 0.89 | (0.81–0.98) | 1.01 | (0.90–1.14) | 0.91 | (0.84–0.99) |
| Unknown | 1.04 | (0.82–1.33) | 0.78 | (0.55–1.07) | 1.18 | (0.95–1.47) |
| SES (% living below poverty) | ||||||
| First tertile (<5.4 %) | 1 | 1 | 1 | |||
| Second tertile (5.4–11.8 %) | 1.02 | (0.91–1.13) | 1.10 | (0.96–1.27) | 0.96 | (0.87–1.06) |
| Third tertile (>11.8 %) | 1.15 | (1.02–1.30) | 1.28 | (1.10–1.49) | 0.99 | (0.89–1.11) |
| SEER Cancer Registry Region | ||||||
| Northeast | 1 | 1 | 1 | |||
| South | 0.84 | (0.73–0.97) | 1.35 | (1.11–1.63) | 0.77 | (0.68–0.87) |
| Midwest | 0.70 | (0.59–0.82) | 2.09 | (1.70–2.56) | 0.51 | (0.44–0.59) |
| West | 0.69 | (0.61–0.78) | 1.37 | (1.15–1.62) | 0.65 | (0.58–0.72) |
| Metropolitan area (yes vs no) | 1.08 | (0.96–1.23) | 0.74 | (0.64–0.85) | 1.27 | (1.14–1.42) |
| Comorbidity scores | ||||||
| 0 | 1 | 1 | 1 | |||
| 1 | 0.95 | (0.86–1.05) | 0.92 | (0.81–1.05) | 1.00 | (0.91–1.10) |
| 2 | 0.81 | (0.71–0.94) | 0.81 | (0.67–0.98) | 0.94 | (0.82–1.06) |
| 3+ | 0.81 | (0.69–0.95) | 0.82 | (0.66–1.02) | 0.92 | (0.78–1.07) |
| Year of diagnosis | ||||||
| 2007 | 1 | 1 | 1 | |||
| 2008 | 0.92 | (0.83–1.03) | 0.94 | (0.82–1.08) | 0.96 | (0.88–1.06) |
| 2009 | 0.98 | (0.89–1.09) | 1.00 | (0.88–1.14) | 0.98 | (0.90–1.08) |
| AJCC tumor stage | ||||||
| Stage I | 1 | 1 | 1 | |||
| Stage II | 1.41 | (1.19–1.67) | 0.78 | (0.62–0.96) | 1.50 | (1.29–1.75) |
| Stage III | 1.17 | (0.90–1.51) | 0.66 | (0.47–0.94) | 1.38 | (1.09–1.73) |
| Tumor size (cm) | ||||||
| <1.0 | 1 | 1 | 1 | |||
| >=1.0 | 1.04 | (0.90–1.21) | 1.15 | (0.96–1.38) | 0.97 | (0.85–1.10) |
| Unknown size | 0.56 | (0.47–0.67) | 1.13 | (0.89–1.42) | 0.57 | (0.48–0.68) |
| Number of positive nodes | ||||||
| 0 (node negative) | 1 | 1 | 1 | |||
| 1+ | 1.30 | (1.10–1.53) | 0.99 | (0.81–1.22) | 1.22 | (1.05–1.40) |
| Unknown | 0.74 | (0.64–0.85) | 0.96 | (0.80–1.17) | 0.77 | (0.67–0.87) |
| Tumor grade | ||||||
| Well differentiated | 1 | 1 | 1 | |||
| Moderately differentiated | 1.25 | (1.13–1.38) | 1.03 | (0.91–1.16) | 1.18 | (1.08–1.29) |
| Poorly differentiated | 1.07 | (0.94–1.22) | 0.99 | (0.83–1.17) | 1.07 | (0.95–1.20) |
| Unknown | 1.13 | (0.91–1.40) | 1.11 | (0.84–1.47) | 1.05 | (0.86–1.28) |
| Surgery treatment | ||||||
| No surgery | 1 | 1 | 1 | |||
| BCS | 0.69 | (0.53–0.91) | 1.69 | (1.08–2.63) | 0.58 | (0.45–0.75) |
| Mastectomy | 0.85 | (0.64–1.12) | 1.53 | (0.98–2.40) | 0.73 | (0.56–0.95) |
| Chemotherapy (yes vs no) | 0.74 | (0.65–0.84) | 0.65 | (0.54–0.77) | 0.95 | (0.85–1.06) |
| Radiation therapy (yes vs no) | 1.65 | (1.48–1.85) | 0.86 | (0.74–1.00) | 1.65 | (1.48–1.83) |
a
Adjusted odds ratio (AOR) controlled for all other socio-demographic and tumor characteristics listed in Table 1